Hypothalamic Amenorrhea, FunctionalHEAL-FHANCT07386223
Health and Lifestyle Support for Functional Hypothalamic Amenorrhea
A study testing Psychoeducaction or treatment as usual and Treatment as usual (TAU) in people with Hypothalamic Amenorrhea, Functional, run by Karolinska Institutet at 1 site in Sweden.
Trial summary
The goal of this clinical trial is to learn whether a 10-week psychoeducational health and lifestyle intervention can help women with Functional Hypothalamic Amenorrhea (FHA) restore their endocrine balance and menstrual cycles. Read more about this study
- Who is it for?
- Ages 18 to 42 years, women only
- Conditions the study is for
- Hypothalamic Amenorrhea, Functional
- What is being tested?
- Psychoeducaction or treatment as usual and Treatment as usual (TAU)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteSweden
- Study dates
- 1 Feb 2026to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 42 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- female
- aged 18-42 years
- fulfill criteria for diagnosis of functional hypothalamic amenorrhea (hypogonadotropic hypogonadism)
- basic proficiency in Swedish
- access to a computer.
Who cannot join
- Lack of proficiency in language
- evere psychiatric co-morbidity e.g. psychosis or active eating disorders (anorexia nervosa).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: HEAL-FHA: Health and Lifestyle Support for Functional Hypothalamic Amenorrhea
The goal of this clinical trial is to learn whether a 10-week psychoeducational health and lifestyle intervention can help women with Functional Hypothalamic Amenorrhea (FHA) restore their endocrine balance and menstrual cycles.
The main questions the study aims to answer are:
Read more
Does the intervention lead to the return of regular menstrual bleeding? Does it improve hormonal markers associated with FHA recovery? To answer these questions, researchers will compare the 10-week psychoeducational intervention with treatment as usual (TAU). This comparison will help determine whether the structured program leads to faster or more reliable recovery of menstrual and endocrine function than the care women typically receive today.
Participants will:
Take part in a 10-week psychoeducational program focusing on health behaviors important for FHA recovery (intervention group) or receive treatment as usual (comparison group) Complete questionnaires and health assessments Provide blood samples to measure hormone levels Take part in a gynecological exam to monitor ovary activity and endometrial thickness Be followed for 9 months after the program to track progress This study builds on a previous feasibility study and will help determine whether the intervention is effective and should be used more widely to support women with FHA.
Read the detailed description
The study a randomized, controlled, multicentre trial evaluating a 10-week psychoeducational health and lifestyle intervention with a 9-month follow-up period in women with Functional Hypothalamic Amenorrhea (FHA).
Background and Significance FHA is a functional endocrine condition that can be reversed through behavioural and lifestyle changes. A structured psychoeducational program may support these changes by improving knowledge, motivation, and self-management skills. The intervention will be compared with treatment as usual (TAU) to determine whether it leads to superior restoration of menstrual and endocrine function.
Study Aim The aim of this study is to evaluate whether a 10-week psychoeducational intervention is effective in restoring menstrual and endocrine function in women with FHA.
Study Setting and Participants A total of 70 women with FHA will be recruited following the same procedures used in Study 1. Participants who meet inclusion criteria and provide informed consent will enter the trial. Those who meet exclusion criteria will receive appropriate clinical information, standard care, or referral to relevant healthcare services.
Power Analysis The sample size calculation is based on findings from a previous trial evaluating an individualized Cognitive Behavioural Therapy (CBT) intervention, where ovarian recovery occurred in 87.5% of participants receiving CBT compared with 33% in the observation group. For the current trial, the psychoeducational intervention is expected to yield a slightly lower effect (estimated 70% recovery). With 80% power and α = 0.05, 28 participants per group are required to detect this difference. Allowing for up to 15% attrition, the study will recruit 35 participants per arm.
Study Design The study uses a two-arm, parallel-group, superiority randomized controlled design with 1:1 allocation. Randomization will be conducted by Karolinska Trial Alliance (KTA). Participants will undergo baseline psychiatric screening with MINI+ and complete validated psychological questionnaires at baseline, post-treatment, and at 9-month follow-up. These assessments will capture stress, coping, symptoms of anxiety and depression, eating disorder symptoms, exercise behaviours, and personality traits associated with FHA. Hormonal analyses will be performed at baseline, post-treatment, and at 3-, 6-, and 9-month follow-up.
Data and Sample Collection The qualitative and quantitative findings from the feasibility study will inform refinement of the final study protocol. All questionnaire data will be collected electronically via REDCap. Hormonal analyses will include repeated measures of LH and additional hormones related to ovarian function. Participants will report all episodes of vaginal bleeding or spotting during the study period. If bleeding occurs, estradiol and progesterone will be measured 21 days later to assess for ovulation.
Outcome Measures The primary outcome is restoration of menstrual function. Secondary outcomes include normalization of luteinizing hormone (LH; reference range 2.4-13 IU/L) as a marker of restored GnRH pulsatility, as well as reductions in self-reported mental health symptoms at 9-month follow-up. Negative effects will be monitored using self-report instruments.
Statistical Analysis Primary treatment response is defined as restoration of menstruation; secondary response is defined as normalization of LH levels. Planned analyses include hypothesis testing of pre-/post-treatment changes using two-sided paired t-tests. Additional analyses will follow a predefined statistical analysis plan.
Ethical Considerations Informed consent will be obtained from all participants. Studies are approved by the Swedish Ethical Review Authority (Dnr 2023-05586-01). An amendment for Study 2 is planned. Participants will complete questionnaires, provide blood samples, and undergo a gynecological examination. The overall risk to participants is considered low, and adverse events will be monitored throughout the study period.
- Conditions
- Hypothalamic Amenorrhea, Functional
- Being tested
- Psychoeducaction or treatment as usual, Treatment as usual (TAU)
- Keywords
- psychoeduction, lifestyle change, menstrual restoration, amenorrhea
- Medical subject headings
- Amenorrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Psychoeducaction or treatment as usualBehavioural
10 week psychoeducaction or treatment as usual
Also called Standard FHA management provided in routine clinical care.
Standard FHA management provided in routine clinical care.
| Study group | Role | What they receive |
|---|---|---|
| Psychoeducational Intervention | Experimental | Participants in this arm will take part in a 10-week psychoeducational health and lifestyle program designed to support behavioural change related to recovery from Functional Hypothalamic Amenorrhea (FHA). The intervention includes weekly modules focusing on nutrition, exercise behaviours, stress management, and recovery-promoting habits, delivered with evidence-based educational content and practical exercises. Participants will also complete questionnaires and provide blood samples at scheduled timepoints and will be followed for 9 months after the intervention. Receives: Behavioral: Psychoeducaction or treatment as usual |
| Treatment as Usual (TAU) | Active comparator | Participants in this arm will receive treatment as usual for Functional Hypothalamic Amenorrhea, which may include general clinical advice, routine follow-up, and standard information provided by healthcare services. No structured psychoeducational program will be offered. Participants will complete questionnaires and provide blood samples at the same timepoints as the intervention group. Receives: Other: Treatment as usual (TAU) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with return of spontaneous menstrual bleeding within 9 months
Restoration of menstruation is defined as a spontaneous menstrual bleed observed reported by the participants. Hormonal assessment will occur on cycle day 21 of the next menstrual cycle following intervention. The outcome will be reported as the number and proportion of participants who experience menstrual restoration.
Measured: Restoration of menstruation after 9 months of follow-up
Change in serum FSH, LH, and estradiol
For participants who have not experienced menstruation during follow-up serum FSH, LH, and estradiol levels will be measured to evaluate hormonal improvement. Changes from baseline will be reported as mean ± SD and as the proportion of participants showing increase in estradiol consistent with improved ovarian function.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start1 Feb 2026 (estimated)
- Primary completion1 Jan 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypothalamic Amenorrhea, FunctionalStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Karolinska University Hospital, FoU Centrum, Landstinget Sörmland
- Responsible party
- Principal investigator, Hedvig Engberg, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07386223
- Sponsor's protocol ID
- 2023-05586-01
- Other IDs
- 2023
- Acronym
- HEAL-FHA
- Status last verified
- Jan 2026
- First submitted
- 19 Jan 2026
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: What data will be shared: De-identified individual participant data collected during the trial, including: Demographics (age, sex) Clinical assessments and questionnaire responses Hormonal measurements (LH, estradiol, progesterone) Menstrual cycle and ovulation data Psychological and behavioral assessments Other documents to be shared: Data dictionary describing all variables and coding used Study protocol and statistical analysis plan
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HEAL-FHA: Health and Lifestyle Support for Functional Hypothalamic Amenorrhea
- ClinicalTrials.gov ID
- NCT07386223
- Acronym / sponsor ID
- HEAL-FHA / 2023-05586-01
- Conditions
- Hypothalamic Amenorrhea, Functional
- Keywords
- psychoeduction, lifestyle change, menstrual restoration, amenorrhea
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- Karolinska University Hospital, FoU Centrum, Landstinget Sörmland
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether a 10-week psychoeducational health and lifestyle intervention can help women with Functional Hypothalamic Amenorrhea (FHA) restore their endocrine balance and menstrual cycles.
The main questions the study aims to answer are:
Does the intervention lead to the return of regular menstrual bleeding? Does it improve hormonal markers associated with FHA recovery? To answer these questions, researchers will compare the 10-week psychoeducational intervention with treatment as usual (TAU). This comparison will help determine whether the structured program leads to faster or more reliable recovery of menstrual and endocrine function than the care women typically receive today.
Participants will:
Take part in a 10-week psychoeducational program focusing on health behaviors important for FHA recovery (intervention group) or receive treatment as usual (comparison group) Complete questionnaires and health assessments Provide blood samples to measure hormone levels Take part in a gynecological exam to monitor ovary activity and endometrial thickness Be followed for 9 months after the program to track progress This study builds on a previous feasibility study and will help determine whether the intervention is effective and should be used more widely to support women with FHA.
Detailed description
The study a randomized, controlled, multicentre trial evaluating a 10-week psychoeducational health and lifestyle intervention with a 9-month follow-up period in women with Functional Hypothalamic Amenorrhea (FHA).
Background and Significance FHA is a functional endocrine condition that can be reversed through behavioural and lifestyle changes. A structured psychoeducational program may support these changes by improving knowledge, motivation, and self-management skills. The intervention will be compared with treatment as usual (TAU) to determine whether it leads to superior restoration of menstrual and endocrine function.
Study Aim The aim of this study is to evaluate whether a 10-week psychoeducational intervention is effective in restoring menstrual and endocrine function in women with FHA.
Study Setting and Participants A total of 70 women with FHA will be recruited following the same procedures used in Study 1. Participants who meet inclusion criteria and provide informed consent will enter the trial. Those who meet exclusion criteria will receive appropriate clinical information, standard care, or referral to relevant healthcare services.
Power Analysis The sample size calculation is based on findings from a previous trial evaluating an individualized Cognitive Behavioural Therapy (CBT) intervention, where ovarian recovery occurred in 87.5% of participants receiving CBT compared with 33% in the observation group. For the current trial, the psychoeducational intervention is expected to yield a slightly lower effect (estimated 70% recovery). With 80% power and α = 0.05, 28 participants per group are required to detect this difference. Allowing for up to 15% attrition, the study will recruit 35 participants per arm.
Study Design The study uses a two-arm, parallel-group, superiority randomized controlled design with 1:1 allocation. Randomization will be conducted by Karolinska Trial Alliance (KTA). Participants will undergo baseline psychiatric screening with MINI+ and complete validated psychological questionnaires at baseline, post-treatment, and at 9-month follow-up. These assessments will capture stress, coping, symptoms of anxiety and depression, eating disorder symptoms, exercise behaviours, and personality traits associated with FHA. Hormonal analyses will be performed at baseline, post-treatment, and at 3-, 6-, and 9-month follow-up.
Data and Sample Collection The qualitative and quantitative findings from the feasibility study will inform refinement of the final study protocol. All questionnaire data will be collected electronically via REDCap. Hormonal analyses will include repeated measures of LH and additional hormones related to ovarian function. Participants will report all episodes of vaginal bleeding or spotting during the study period. If bleeding occurs, estradiol and progesterone will be measured 21 days later to assess for ovulation.
Outcome Measures The primary outcome is restoration of menstrual function. Secondary outcomes include normalization of luteinizing hormone (LH; reference range 2.4-13 IU/L) as a marker of restored GnRH pulsatility, as well as reductions in self-reported mental health symptoms at 9-month follow-up. Negative effects will be monitored using self-report instruments.
Statistical Analysis Primary treatment response is defined as restoration of menstruation; secondary response is defined as normalization of LH levels. Planned analyses include hypothesis testing of pre-/post-treatment changes using two-sided paired t-tests. Additional analyses will follow a predefined statistical analysis plan.
Ethical Considerations Informed consent will be obtained from all participants. Studies are approved by the Swedish Ethical Review Authority (Dnr 2023-05586-01). An amendment for Study 2 is planned. Participants will complete questionnaires, provide blood samples, and undergo a gynecological examination. The overall risk to participants is considered low, and adverse events will be monitored throughout the study period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Psychoeducational Intervention | Experimental | Behavioral: Psychoeducaction or treatment as usualParticipants in this arm will take part in a 10-week psychoeducational health and lifestyle program designed to support behavioural change related to recovery from Functional Hypothalamic Amenorrhea (FHA). The intervention includes weekly modules focusing on nutrition, exercise behaviours, stress management, and recovery-promoting habits, delivered with evidence-based educational content and practical exercises. Participants will also complete questionnaires and provide blood samples at scheduled timepoints and will be followed for 9 months after the intervention. |
| Treatment as Usual (TAU) | Active comparator | Other: Treatment as usual (TAU)Participants in this arm will receive treatment as usual for Functional Hypothalamic Amenorrhea, which may include general clinical advice, routine follow-up, and standard information provided by healthcare services. No structured psychoeducational program will be offered. Participants will complete questionnaires and provide blood samples at the same timepoints as the intervention group. |
Who may qualify
- Ages
- 18 to 42 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- female
- aged 18-42 years
- fulfill criteria for diagnosis of functional hypothalamic amenorrhea (hypogonadotropic hypogonadism)
- basic proficiency in Swedish
- access to a computer.
Key exclusion criteria (2 listed)
- Lack of proficiency in language
- evere psychiatric co-morbidity e.g. psychosis or active eating disorders (anorexia nervosa).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Psychoeducaction or treatment as usual10 week psychoeducaction or treatment as usual | Behavioural | Psychoeducational Intervention |
| Treatment as usual (TAU)Also: Standard FHA management provided in routine clinical care.Standard FHA management provided in routine clinical care. | Other | Treatment as Usual (TAU) |
Primary outcome
Number of participants with return of spontaneous menstrual bleeding within 9 months
Time frame: Restoration of menstruation after 9 months of follow-up
Restoration of menstruation is defined as a spontaneous menstrual bleed observed reported by the participants. Hormonal assessment will occur on cycle day 21 of the next menstrual cycle following intervention. The outcome will be reported as the number and proportion of participants who experience menstrual restoration.
Change in serum FSH, LH, and estradiol
Time frame: 12 months
For participants who have not experienced menstruation during follow-up serum FSH, LH, and estradiol levels will be measured to evaluate hormonal improvement. Changes from baseline will be reported as mean ± SD and as the proportion of participants showing increase in estradiol consistent with improved ovarian function.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Individual participant dataSharing planned: Yes. What data will be shared: De-identified individual participant data collected during the trial, including: Demographics (age, sex) Clinical assessments and questionnaire responses Hormonal measurements (LH, estradiol, progesterone) Menstrual cycle and ovulation data Psychological and behavioral assessments Other documents to be shared: Data dictionary describing all variables and coding used Study protocol and statistical analysis plan
Related trials for Hypothalamic Amenorrhea, Functional
Recruiting
Feasibility of a Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA Pilot)
Functional Hypothalamic Amenorrhea
RecruitingPhase 2
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
Functional Hypothalamic Amenorrhea, FHA
RecruitingPhase 2
Role of Estrogen on Skeletal Outcomes in FHA
Bone Strength, Bone Density
Active, not recruitingObservational study
Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH)
Hypothalamic Amenorrhea
Not yet recruiting
Effects of Resistance Training on Women With Functional Hypothalamic Amenorrhea
Amenorrhea, Functional Hypothalamic Amenorrhea (FHA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Psychoeducaction or treatment as usual and Treatment as usual (TAU) in people with Hypothalamic Amenorrhea, Functional, run by Karolinska Institutet at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hedvig Engberg, MD PhD (+46 08 123 795 02, hedvig.engberg@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with return of spontaneous menstrual bleeding within 9 months (time frame: Restoration of menstruation after 9 months of follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.